teleo-codex/domains/health/glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	related
claim	health	Primary care physicians prescribe GLP-1 agonists as metabolic drugs without understanding their direct psychiatric mechanisms, creating a supervision gap for reward pathway modulation	experimental	Dr. Will Sauvé (Osmind CMO), Dr. Annette Bosworth, Dr. Brittany Albright	2026-05-07	GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification	vida	health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md	structural	Osmind	human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone value-based-care-transitions-stall-at-the-payment-boundary glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population

GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification

GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric monitoring infrastructure. Dr. Sauvé states: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' The competency gap is structural: psychiatrists manage patients on GLP-1s they didn't prescribe, without understanding central mechanisms, dosing nuances, or psychiatric side effects. This creates a supervision gap for drugs that directly modulate dopaminergic reward circuits — the same circuits targeted by psychiatric medications. The gap exists because the drugs are classified and prescribed as metabolic agents despite their primary mechanism involving psychiatric circuitry. This is distinct from the general GLP-1 prescribing competency gap because it specifically concerns the mismatch between psychiatric mechanism and non-psychiatric prescriber training.